| Clinical Trial Stage Projects | Marco Londei | A Phase 1/2a First-in-Human, Dose-Escalation Study to Evaluate TRX319 in Subjects with Progressive Multiple Sclerosis |
$8,000,000 |
| Clinical Trial Stage Projects | Maria Grazia Roncarolo | TRX103 for prevention of GvHD in patients receiving HLA mismatched HSCT for the treatment of hematologic malignancies |
$8,000,000 |
| Late Stage Preclinical Projects | Maria Grazia Roncarolo | TRX103 for prevention of GvHD in patients receiving HLA mismatched related or unrelated allogeneic HSCT for the treatment of hematologic malignancies. |
$4,000,000 |
